https://adisinsight.springer.com/drugsafety/803887548?error=cookies_not_supported&code=a41ecffe-3ddb-4681-9184-3617cc322253
Telitacicept - AdisInsight
In a retrospective multicenter study involving 97 patients, conducted between 1 April 2021 to 1 April 2023, two patients [ages and sexes not stated] were
adisinsight
https://herenciageneticayenfermedad.blogspot.com/2024/04/resultados-positivos-con-telitacicept.html
herenciageneticayenfermedad: Resultados positivos con telitacicept en el lupus eritematoso...
resultadospositivosconenel
https://adisinsight.springer.com/drugsafety/803925908?error=cookies_not_supported&code=10945a1b-fbe9-48dc-9474-d6b9e212d26f
Telitacicept - AdisInsight
A 25-year-old woman with systemic lupus erythematosus (SLE) was exposed to telitacicept during early pregnancy, representing a case of maternal exposure. She
adisinsight
https://adisinsight.springer.com/trials/700369007?error=cookies_not_supported&code=89d35b18-90f3-4d95-96d6-01761d95b141
Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus...
The effect of Telitacicept treatment on the changes of transitional regulatory B lymphocyte T1, T2B cell subsets and plasma blasts and the expression levels of
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1509143/full
Frontiers | Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA...
Clinical management of the rare and complex overlapping syndrome of MOG-antibody disease and anti-NMDAR encephalitis (MNOS), which has an uncertain pathogene...
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1268929/full
Frontiers | Case report: Successful treatment of refractory membranous nephropathy with telitacicept
Despite various treatment methods, the remission rate of membranous nephropathy remains limited. Refractory membranous nephropathy especially lacks effective...
case reportmembranous nephropathyfrontierssuccessfultreatment
https://adisinsight.springer.com/trials/700361950?error=cookies_not_supported&code=3164c30c-842b-467f-96e1-99815150c7a3
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study of Telitacicept in...
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.
https://adisinsight.springer.com/drugsafety/803926049?error=cookies_not_supported&code=9195ee31-71ab-4bcb-9843-eba83728d8c9
Telitacicept - AdisInsight
A 34-year-old woman with neuropsychiatric systemic lupus erythematosus (NPSLE) developed progressive quadriparesis, bilateral ptosis and facial palsy over one
adisinsight